Publication date: September 2017
Source:European Journal of Cancer, Volume 83
Author(s): Nicolas Penel, Axel Le Cesne, Sylvie Bonvalot, Antoine Giraud, Emmanuelle Bompas, Maria Rios, Sébastien Salas, Nicolas Isambert, Pascaline Boudou-Rouquette, Charles Honore, Antoine Italiano, Isabelle Ray-Coquard, Sophie Piperno-Neumann, François Gouin, François Bertucci, Thomas Ryckewaert, Jean-Emmanuel Kurtz, Françoise Ducimetiere, Jean-Michel Coindre, Jean-Yves Blay
PurposeThe outcome of desmoid-type fibromatosis (DTF) is unpredictable. Currently, a wait-and-see approach tends to replace large en bloc resection as the first therapeutic approach. Nevertheless, there are no validated factors to guide the treatment choice.MethodWe conducted a prospective study of 771 confirmed cases of DTF. We analysed event-free survival (EFS) based on the occurrence of relapse after surgery, progressive disease during the wait-and-see approach, or change in therapeutic strategy. Identification of prognostic factors was performed using classical methods (log-rank test and Cox model).ResultsOverall, the 2-year EFS was 56%; this value did not differ between patients undergoing an operation and those managed by the wait-and-see approach (53% versus 58%, p = 0.415). In univariate analysis, two prognostic factors significantly influenced the outcome: the nature of diagnostic sampling (p = 0.466) and primary location (p = 0.0001). The 2-year EFS was only 32% after open biopsy. The 2-year EFS was 66% for favourable locations (abdominal wall, intra-abdominal, breast, digestive viscera and lower limb) and 41% for unfavourable locations. Among patients with favourable locations, the 2-year EFS was similar in patients treated by both surgery (70%) and the wait-and-see approach (63%; p = 0.413). Among patients with unfavourable locations, the 2-year EFS was significantly enhanced in patients initially managed with the wait-and-see approach (52%) compared with those who underwent initial surgery (25%; p = 0.001).ConclusionThe location of DTF is a major prognostic factor for EFS. If these findings are confirmed by independent analysis, personalised management of DTF must consider this easily obtained parameter.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2ubpJKG
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers British Journal of Cancer 116, 1425 (23 May 2017). ...
-
Objective A systematic review and meta-analysis to investigate the impact of electronic nicotine delivery systems (ENDS) and/or electronic n...
-
Publication date: April 2017 Source: European Journal of Cancer, Volume 75 Author(s): A. Ieni, G. Angelico, P. Zeppa, G. Tuccari fro...
-
Ecohydrological responses to climate change will exhibit spatial variability and understanding the spatial pattern of ecological impacts is ...
-
Abstract Maternal obesity is associated with large-for-gestational-age (LGA) neonates and programming of obesity-related cardiovascular d...
-
Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. ...
-
Communicating with patients at the end of life is regarded as a difficult task, and speaking openly about death is often avoided.1,2 Around ...
-
A. M. Y. Yong, SS Yang, KB Tan, SA Ho Indian Dermatology Online Journal 2017 8(3):192-194 The Trichosporon species are yeast-like opport...
-
Abstract Previous data has shown that the risk of nodal metastases is significantly greater for classical papillary thyroid carcinoma (PTC...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου